Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 42

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 42
---
 incentive compensation; and (3) equity-based incentive awards. A significant portion of target executive pay is “at risk” or based on meeting performance goals to align executive pay with our long-term goals and the interests of our shareholders. The following charts demonstrate 29

the 2024 pay mix for our Chief Executive Officer and the average pay mix for the other named executive offers as a group.

The compensation of our executive officers during 2024 is consistent with business achievements and individual performance over the course of the year. Annual Base Salary The annual base salaries of our named executive officers are generally determined, approved and reviewed periodically by our compensation committee and, with respect to our Chief Executive Officer, our board of directors, based on the recommendation of the compensation committee, to compensate our named executive officers for the satisfactory performance of duties to Repare. Annual base salaries are intended to provide a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and responsibilities. Base salaries for our named executive officers generally have been positioned at the market median level to attract and retain individuals with superior executive talent. Individual pay levels may be above or below the market median based on the experience the individual brings to the table, including their scope of position and performance, and considering internal pay equity. The following table sets forth the annual base salaries for each of our named executive officers for the periods presented:

| Named Executive Officer       |     | 2024 Base Salary 
 ($)              |         |     | 2023 Base Salary 
 ($)              |         |     | Change from 
 2023        
 (%)         |   |
| Lloyd M. Segal(1)             |     |                  | 630,500 |     |                  | 615,000 |     |             | 3 |
| Maria Koehler, M.D., Ph.D.(2) |     |                  | 505,000 |     |                  | 493,500 |     |             | 2 |
| Michael Zinda, Ph.D.          |     |                  | 474,500 |     |                  | 463,000 |     |             | 2 |

| (1) | Mr. Segal resigned from his position as our Chief Executive Officer effective as of April 11, 2025. |

| (2) | Dr. Koehler departed from her position as our Chief Medical Officer effective as of March 31, 2025. |

For 2024, our board of directors and the compensation committee, as applicable